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Considering the female predominance in most of the autoimmune disorders that associate with the PTPN22 Trp620 variant and
the complexity by which this variant influences immunologic tolerance, the objective of this study was to ascertain if the allele-
specific expression of the disease-associated Arg620Trp polymorphism is affected by cis-acting or sex-specific trans-acting
factor/s (e.g. sex-hormones). The use of the allele-specific transcript quantification of the Arg620Trp encoding 1858T
polymorphism revealed no difference in the expression of the 1858C- and T-alleles in non-stimulated peripheral blood
mononuclear cells (PBMCs) from non-pregnant female subjects, male subjects or pregnant female subjects in first or third
trimester (P¼ 0.70), respectively. While the transcription of PTPN22 in anti-CD3/anti-CD28 stimulated PBMCs increased
fourfold (Po0.0001) and 13-fold (Po0.0001) after 48 and 72 h of activation, respectively, the expression of PTPN22 1858C-
and T-alleles increased to the same extent (P¼ 0.64). The present result essentially excludes such phenomena as a partial
explanation for the female predominance in most of the autoimmune disorders that associate with the PTPN22 Trp620 variant.
Genes and Immunity (2007) 8, 131–137. doi:10.1038/sj.gene.6364369; published online 18 January 2007
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Introduction
The lymphoid-specific phosphatase (LYP) encoded by
PTPN22 (protein tyrosine phosphatase non-receptor type
22; 1p13.3-p13.1) plays a very central role in maintaining
immunologic tolerance and preventing autoimmunity.
Since the first published association between a PTPN22
Trp620 variant (PTPN22 1858C to T changes codon 620
from arginine into tryptophan) and type 1 diabetes,1 it
has become apparent that the PTPN22 Trp620 variant
is the strongest common genetic risk factor for human
autoimmunity outside the major histocompatibility
complex, with association with a wide variety of
autoimmune diseases that have a prominent humoral
component (systemic lupus erythematosus: e.g. Kyogoku
et al.;2 rheumatoid arthritis: e.g. Begovich et al.;3 Graves’
disease: e.g. Velaga et al.;4 Addison’s disease: e.g. Velaga
et al.;4 Hashimoto’s thyroiditis5). It is intriguing that the
PTPN22 Trp620 variant apparently is a gain-of-function
variant,6 but the mechanism by which the PTPN22
Trp620 variant exerts the disease-promoting effect has
yet to be established.
LYP is specifically expressed in lymphocytes3,7 and by
dephosphorylating and inactivating TCR-associated
kinases Lck, Fyn, and ZAP-70, LYP is one of the most
powerful inhibitors of T-cell activation.8,9 Mice knockout
of the murine homolog of LYP called PEP (PEST domain-
enriched tyrosine phosphatase) on a C57/Bl6 back-
ground show a lowering of the threshold for T-cell
receptor signaling and an enhanced expansion of effector
and memory T-cell population and increased serum
immunoglobulin levels.10 The PTPN22 1858T changes
codon 620 from arginine into tryptophan and the effect of
this amino acid change on LYP function has not been
entirely defined but one consequence is to disrupt the
interaction with an intracellular C-terminal Src tyrosine
kinase (Csk),1,3 known to be an important suppressor
of kinases that mediate T-cell activation. The disease-
predisposing PTPN22 Trp620 is located in the N-
terminal-SH3 binding domain of the protein, and the
mutant protein fails to bind the SH3 domain of Csk.1
Unexpectively, the human PTPN22 Trp620 disease-
associated variant has recently been found to be a gain
of function variant, with increased catalytic activity
compared to the nonassociated variant encoded by
PTPN22 Arg620.6 It currently remains unclear how this
potential increase in the inhibition of TCR activation
might lead to autoimmunity. A current hypothesis
postulates that the threshold for TCR signaling during
thymic development is elevated in individuals expres-
sing the mutant LYP protein, resulting in defective
negative selection and survival of autoreactive T cells
that would normally have undergone apoptosis.11
Further, an altered LYP function in peripheral
CD4þCD25þ T regulatory cells, making them less potent
in suppressing immune responses against autoantigens,
has been suggested.11
Owing to this apparent complexity, we aimed to
investigate whether cis-acting factors existed that inter-
fered with the expression of the PTPN22 Trp620-
encoding variant and thus could explain the association
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of this allele with autoimmune diseases. Moreover, we
wanted to see if sex related trans factors could influence
transcription of this allele in an allele-specific way
considering the female predominance in most of the
autoimmune disorders that associate with the PTPN22
Trp620 variant and autoimmune diseases in general.12
Several recent studies have indicated that a large
proportion of human non-imprinted autosomal genes are
subject to variable cis-acting influences resulting in
differences in the allele-specific expression of the
genes.13–16 Quantitative differences in allelic gene expres-
sion between individuals may contribute to the genetic
basis for phenotypic differences and may play an
important role in the development of complex diseases.
We applied a quantitative method (fluorescent PCR-
RFLP analysis) of allele discrimination to DNA and
cDNA samples purified from peripheral blood mono-
nuclear cells (PBMCs) obtained from healthy male
subjects, female subjects, female subjects in the first
trimester of pregnancy and female subjects in the third
trimester of pregnancy, heterozygous for C1858T. Addi-
tional variations in allelic expression may manifest in a
cell type or state-specific manner,13 and as T cells play a
role at least in the initiation phase of the autoimmune
disorders that associate with the PTPN22 R620W poly-
morphism, we further investigated the allele-specific
expression over time in activated T cells from hetero-
zygous individuals.
Results
Fragment length analysis by capillary electrophoresis
Following fragment length analysis by capillary electro-
phoresis, samples from individuals heterozygous for
C1858T showed three FAM-coupled fragments of 218,
176 and 42 bp, whereas those homozygous for CC
showed two FAM-coupled fragments of 176 and 42 bp
(Figure 1). Visualization of both FAM- and NED-coupled
fragments was allowed, and the absence of a NED-
coupled 148-bp fragment and presence of a NED-
coupled 104 bp fragment demonstrated complete cutting
by the RsaI endonuclease throughout the study.
Sex-specific relative allelic expression
Genomic DNA samples did not deviate from the
expected equimolar ratio of alleles, indicating that the
present assay amplify and visualize the two alleles with
the same area, and rejecting that putative gene dosage
effects or other biases influenced the measured allelic
ratio in cDNA samples (P¼ 0.21; Two-way Repeated
Measures analysis of variance (ANOVA), Figure 2).
Therefore, no correction of cDNA peak height in each
individual sample was necessary.
There was no overall effect of DNA type (genomic
DNA and cDNA) on the relative expression of the T-
allele in PBMCs (P¼ 0.08; Two-way Repeated Measures
ANOVA, Figure 2), suggesting that the PTPN22 locus is
unlikely to contain common polymorphisms or epige-
netic modification that alter PTPN22 mRNA levels in
non-stimulated PBMCs, assayed by the level of allele-
specific expression of the PTPN22 Arg620Trp poly-
morphism.
Nor was there any effect of sex and pregnancy status
on the relative expression of the T-allele (P¼ 0.70; Two-
way Repeated Measures ANOVA, Figure 2), indicating
the absence of sex-specific trans-acting factor/s (e.g. sex-
hormones) affecting the expression of the PTPN22
Arg620Trp-encoding allele relative to the wild-type allele
in non-stimulated PBMCs. For every ANOVA, P-values
were Bonferroni adjusted for the number of comparisons.
Repeat assays showed good reproducibility of indivi-
dual cDNA allelic ratios with an average s.d. of 0.03.
Regulation of PTPN22 mRNA and relative allelic expression
in stimulated PBMCs over time
The mRNA Induction index of PTPN22 in PBMCs
remained relatively unchanged until 48 h of anti-CD3
and anti-CD28 stimulation, where the mRNA expression
of PTPN22 was upregulated approximately four times
compared to non-stimulated cells (Po0.0001; One-way
Repeated Measures ANOVA, Figure 3a). Following 72 h
of stimulation, the mRNA expression of PTPN22 was
further upregulated compared to 48 h of stimulation
(Po0.0001) and reached an approximately 13 times
higher level compared to non-stimulated PBMCs
(Po0.0001; One-way Repeated Measures ANOVA,
Figure 3a). The level of DNA contamination was low as
no-reverse transcription (NRT) controls always resulted
in CT values higher than the 40 cycles detected in the
Figure 1 Fragment length analysis by capillary electrophoresis of
PTPN22 PCR products. TET- and FAM-coupled fragments are
shown in black and blue, respectively. Only FAM-coupled fragments
at 218 and 176 bp appear in the shown length interval and size
markers are not visualized for clarity reasons. (a) Non-cleaved FAM-
labelled and NED-labelled PCR products, (b) cleavage reaction
products of a C1858C homozygous sample, (c) cleavage reaction
products of a T1858T homozygous sample and (d) cleavage reaction
products of a C1858T heterozygous sample. Absence of a NED-
coupled 148-bp fragment and presence of a NED-coupled 104 bp
fragment demonstrates complete cutting by the RsaI endonuclease.
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reverse transcription-polymerase chain reaction (RT-
PCR).
There was no difference in the relative allelic expres-
sion of the C1858T single nucleotide polymorphism
(SNP) between PBMCs stimulated with anti-CD3 and
anti-CD28 for 0, 6, 24, 48 and 72 h, respectively (P¼ 0.64;
One-way Repeated Measures ANOVA; Figure 3b).
Discussion
Considering the female predominance in most of the
autoimmune disorders that associate with the PTPN22
Trp620 variant and the apparent and not well under-
stood complexity by which this variant influences the
immunologic tolerance, we found it relevant to investi-
gate the existence of cis-acting or sex-specific trans-acting
factor/s (e.g. sex-hormones) affecting the allele-specific
expression of the PTPN22 Arg620Trp polymorphism.
The expression of genes conferring susceptibility to
autoimmune disease may be regulated by sex hormones,
and this sex-specific regulation could affect transcript
synthesis or stability at the allele-specific level. The
molecular basis for transcriptional regulation of gene
expression is the binding of trans-acting proteins
(transcription factors) to cis-acting sequences (binding
sites). Polymorphic cis-acting sequences affect RNA
transcript synthesis or stability, or the translational
efficiency and protein stability in an allele-specific
manner and are situated close to the gene(s) that they
regulate.17 Several recent studies have indicated that a
large proportion of human non-imprinted autosomal
genes are subject to variable cis-acting influences on their
expression, resulting in differences in the allele-specific
expression of the genes.13–16 Further, alleles with altered
expression have been associated to the polymorphism
originally linked to human disease,15,18,19 and we
speculated whether the PTPN22 gene also is subject to
cis-acting influence on its expression.
Figure 2 Comparison between genomic DNA and cDNA ratios
assayed at the PTPN22 1858C/T SNP. Data are expressed (n¼ 10–
12) as ratio of T:C alleles. The data are the peak area averages of two
measurements for each individual sample.
Figure 3 (a) Changes in the mRNA Induction index of PTPN22 in
PBMCs stimulated with anti-CD3 and anti-CD28 over time (n¼ 10).
Data are shown as mean7s.d. and values with shared letters are not
significantly different (P40.05); (b) allele-specific expression
assayed at the PTPN22 1858C/T SNP in the same anti-CD3 and
anti-CD28 over time. Data are expressed (n¼ 10) as ratio of T:C
alleles. The data are the peak area averages of two measurements
for each individual sample.
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The predominance of autoimmune disease among
women has focused attention on the role of sex
hormones, mainly estrogen, progesterone and testoster-
one, as primary mediators of the sex differences.20 One
way estrogens exert their biological effect is through
nuclear estrogen receptors (ERs), which interact with
promoter elements to regulate gene transcription.21
Although no potential targets of ER in the promoter of
PTPN22 were found, the existence of putative sex-
specific trans-acting factor/s affecting the allele-specific
expression of PTPN22, was investigated in heathy males,
non-pregnant female subjects, pregnant female subjects
in first and third trimester, respectively, during which the
estrogen and progesterone levels increase greatly.
We developed a fragment length analysis by capillary
electrophoresis using the natural RsaI reaction-restriction
fragment length polymorphism at the PTPN22 C1858T
SNP with complete cutting by the RsaI endonuclease
throughout the study. There was no deviation from the
expected 1:1 ratio of the two alleles in genomic DNA
samples from heterozygous individuals, showing that no
inequality in allelic representation was introduced by the
assay, and rejecting that putative gene dosage effects or
other biases influenced the measured allelic ratio in
cDNA samples. There was no difference in the relative
expression of the PTPN22 1858T-allele between genomic
DNA and cDNA samples from non-stimulated human
PBMCs, suggesting that the PTPN22 locus is unlikely to
contain common polymorphisms or epigenetic modifica-
tion that alter PTPN22 mRNA levels in non-stimulated
PBMCs, assayed by the level of allele-specific expression
of the PTPN22 Arg620Trp polymorphism. Further, there
was no effect of sex or pregnancy status on the relative
expression of the PTPN22 1858T-allele, indicating the
absence of sex-specific trans-acting factor/s (e.g. sex-
hormones) affecting the allele-specific transcription
efficiency or RNA stability of the PTPN22 Arg620Trp
polymorphism in non-stimulated PBMCs.
This essentially excludes such phenomena as a partial
explanation for the female predominance in most of the
autoimmune disorders that associate with the PTPN22
Trp620 variant. It should be noted that cis-acting variants,
besides affecting RNA transcript synthesis or stability,
which is measured in the present study, may affect the
translational efficiency and protein stability. Based on the
present results, it cannot be ruled out that the transla-
tional efficiency of the two PTPN22 Arg620Trp alleles
and/or the stability of the variant and wild-type LYP
proteins are affected by sex-specific factors.
Additional allelic variation in expression may manifest
in a cell type or cell state-specific manner,13 and as T cells
play a role at least in the initiation phase of the auto-
immune disorders that associate with the C1858T poly-
morphism, we further investigated whether the PTPN22
gene is subject to allele-specific regulation during T-cell
activation. While the transcription of PTPN22 in anti-
CD3 and anti-CD28 stimulated PBMCs increased 4- and
13-fold by 48 and 72 h post-activation, respectively, no
allele-specific response to the stimulation was observed
at any sample time points during the experiment. Sex-
stratification was not possible due to the small sample
size and as the stimulated cells were harvested from
healthy individuals, any putative disease-dependent
differences in the relative allelic expression of the
C1858T SNP during T-cell activation was not investigated.
Several recent studies inbred mouse strain,22 chicken,23
human fetuses24 suggest that allelic expression differ-
ences in non-imprinted autosomal genes occur at a
tissue-specific level, suggesting that the transcription
factors that bind to cis-acting elements may vary in
abundance or in ability to function in different tissues.
Theoretically, sex-specific differences in the allele-specific
regulation in the selection of thymocytes during thymic
differentiation, could lead to higher risk of female
subjects heterozygous for the PTPN22 C1858T SNP to
develop autoimmune diseases.
In conclusion, comparison between cDNA from non-
stimulated and anti-CD3 and anti-CD28 stimulated
PBMCs revealed that the expression of PTPN22 1858C-
and T alleles are greatly increased by stimulation but to
the same extent. Furthermore, the absence of any
significant sex-specific variability in relative mRNA
allele ratio suggests that the PTPN22 locus is unlikely
to contain common polymorphisms or epigenetic mod-
ification that alter PTPN22 mRNA levels in non-
stimulated PBMCs and during T-cell activation, and
essentially exclude such phenomena as a partial expla-
nation for the female predominance in most of the
autoimmune disorders that associate with the PTPN22
Trp620 variant and autoimmune diseases in general.
Materials and methods
RFLP analysis (genotyping)
Genomic DNA was extracted from peripheral blood
leukocytes using DNA extraction with proteinase K as
described previously.25 The PTPN22 C1858T polymorph-
ism creates a natural RsaI restriction fragment length
polymorphism (RFLP) with the C (GTAC) but not the T
(GTAT) allele cleaved by the restriction enzyme. Indivi-
duals heterozygous for the PTPN22 C1858T SNP were
selected following genotyping by RFLP analysis as
described previously.26 Samples showing one 218 bp
band were typed as homozygous TT, samples displaying
both 176 and 42 bp bands were typed as homozygous
CC, and samples exhibiting 218, 176 and 42 bp bands
were typed as heterozygous.
Relative expression of 1858T- and C-allele by fluorescent
PCR-RFLP analysis
To investigate whether a sex-specific differential expres-
sion of the PTPN22 C1858T alleles exists, a fluorescent
PCR-RFLP analysis was established to discriminate
between the two allele-specific transcripts.
cDNA synthesis. Mononuclear cells from 1 ml of fresh
full blood from healthy males, non-pregnant female
subjects, and female subjects in the first and third
trimester of pregnancy were isolated using Ficoll-Hypa-
que gradient centrifugation and thawed. mRNA extrac-
tion was performed using the MagAttract kit (Qiagen,
Hilden, Germany) and KingFisher mL (Thermo Labsys-
tems, Helsinki, Finland). cDNA synthesis was performed
using an oligo-dT reverse primer (Applied Biosystems,
Foster City, CA, USA) and the following temperature
profile: 421C for 30 min and 941C for 5 min. A NRT control
was assayed alongside the RT reaction for each individual.
Polymerase chain reaction. For the fluorescent capillary
electrophoresis, the PCR was performed using a forward
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primer (50-ACTGATAATGTTGCTTCAACGG-30) labeled
at its 50 end with the fluorescent dye FAM (6-carboxy-
fluorescein) and a reverse primer: 50-TCAC
CAGCTTCCTCAACCAC-3026 designed to amplify a
218 bp FAM-labeled fragment of the coding region of
PTPN22 containing the C1858T SNP. PCR amplification
was performed in a total reaction volume of 25 ml
containing the following reagents: For genomic DNA:
1ml (50 ng) of genomic DNA, 1.25 ml (5.0 pmol/ml) of
each primer, 2ml dNTP (2.5 mM), 2.5ml 10 PCR buffer
(Applied Biosystems) containing 15 mM MgCl2, and
0.25ml AmpliTaq Gold polymerase (Applied Biosys-
tems). For cDNA: 10 ml of cDNA, 1.0 ml (5.0 pmol/ml) of
each primer, 2.5ml 10 PCR buffer (Applied Biosystems)
without MgCl2, 0.5 ml MgCl2 (25 mM) and 0.125 ml Taq
polymerase (Applied Biosystems).
Amplification was carried out using the following
specific temperature cycling profile: an initial hold at
941C for 12 min (genomic DNA) or 2 min (cDNA); 30
cycles of 941C for 30 s, 601C for 30 s and 721C for 30 s; and
a final extension step of 721C for 7 min.
Cleavage control. A 284-bp fragment of the coding
region of PTPN22 containing the C1858T SNP was
amplified (forward primer: 50-CCTCCTGGGTTTGTA
CCTTA-30; reverse primer: 50-TCACCAGCTTCCTCA
ACCAC-30) using cDNA from a CC homozygous healthy
individual. The PCR amplification conditions were the
same as above with 30 PCR cycles. The PCR fragments
were ligated into the pCR2.1-TOPO (Invitrogen, Taastr-
up, Denmark) cloning vector (using the manufacturer’s
instructions) and transfected into competent bacteria that
were spread on carbenicillin (Sigma, Vallensbæk, Den-
mark) and X-gal (Qbiogen via KemEnTec, Copenhagen,
Denmark) containing agar plates for selection. Positive
clones were grown overnight in carbenicillin supple-
mented LB-media and plasmids were purified using
Wizard SV 9600 Plasmid Purification System (Promega
via Ramcon, Birkerød, Denmark).
Using purified plasmids (1:50) as template, a 148-bp
fragment was amplified (forward primer: 50-
GAATTTCCTTTGGATTGTTC-30; reverse primer: 50-
TCACCAGCTTCCTCAACCAC-30) with the forward
primer being labelled at its 50-end with the fluorescent
dye NED (2,70,80-benzo-50-fluoro-20,4,7-trichloro-5-car-
boxyfluorescein). PCR amplification using the same
condition as above and the following specific tempera-
ture cycling profile: an initial hold at 941C for 2 min; 35
cycles of 941C for 30 s, 601C for 30 s, and 721C for 30 s;
and a final extension step of 721C for 10 min.
The NED-labelled 148-bp fragment PCR product was
used as an internal cleavage control to demonstrate
complete cutting by the RsaI endonuclease in each
cleavage reaction, performed as described below.
Cleavage reaction. Initially labelled PCR products
were digested by RsaI. The reaction conditions were as
follows: 8ml of FAM-labelled PCR product, 1ml of NED-
labelled PCR product and 1000 U/ml RsaI incubated at
371C overnight. Each sample was tested in duplicate and
in two dilutions (undiluted and 1:10) to check for
reproducibility. To check for any significant level of
genomic DNA amplification, NRT controls were run in
duplicates for each sample. Throughout the study, RNA
samples did not yield detectable levels of product in the
absence of an RT step. As an additional control of the
complete cutting by the RsaI endonuclease in the
cleavage reactions, a separate cleavage reaction of a
FAM-labelled PCR product using cDNA from a PTPN22
1858CC homozygous healthy individual was included in
every PCR-RFLP analysis.
Fragment length analysis by capillary electrophoresis
Two microliters of the fluorescently labelled cleavage
reaction products were mixed well with a mixture
containing 0.5 ml of the GeneScan ROX-labelled G-350
size standard (Applied Biosystems) and 13.5 ml of Hi-Di
Formamide (Applied Biosystems).
The mixture was denatured for 5 min at 951C and
placed on ice for 5 min, and to resolve the RFLP profiles,
the fragments were size-separated using a four-color-
laser-induced 16-capillary electrophoresis system (ABI
Prism 3100 Genetic Analyzer), polymer POP 7 and 1
Genetic Analyzer buffer with EDTA (PE Applied
Biosystems). The results were collected and the magni-
tudes of peak heights for all samples were determined
using the ABI Genescan and Genemapper software
(Applied Biosystem, Foster City, CA, USA).
Absence of a NED-coupled fluorescent 148-bp frag-
ment and presence of a 104 bp fragment was used as an
internal control demonstrating complete cutting by the
RsaI endonuclease. Throughout the study failure of the
restriction enzyme was never seen.
Relative allelic expression analysis. For each cDNA sam-
ple from heterozygous individuals, the relative expres-
sion of the PTPN22 1858T- and 1858C-allele was
calculated as the ratio of the peak areas of the 218-bp
fragment and the 176-bp fragment. The same PCR and
analytic conditions were used for gDNA and cDNA to
allow, if necessary, the use of the ratios observed from
gDNA to correct the allelic ratios obtained from cDNA
analyses for any inequalities in allelic representation
introduced by fluorescent dye bias.
Relative expression of PTPN22 mRNA and relative allelic
expression in stimulated T cells over time
Using Ficoll-Hypaque gradient centrifugation, PBMCs
were isolated from full blood from 10 healthy individuals
heterozygous for the PTPN22 C1858T polymorphism.
PBMCs were cultured in complete medium (1106
cells/ml) consisting of RPMI 1640 supplemented with
10% heat-inactivated AB-serum, 200 mM L-glutamine,
100 U/ml penicillin G and 100mg/ml streptomycin
sulphate (Invitrogen Corporation). To assess the effects
of T-cell activation, cells were stimulated with 1 mg/ml
anti-CD3mAb (clone OKT-3; Ortho Biotech, Bridgewater,
NJ, USA) and 0.05mg/ml anti-CD28 mAb (clone CD28.1;
DAKO A/S, Glostrup, Denmark) in 96-wells (Nunc)
microtiter plates incubated at 371C in an atmosphere
with 5% CO2. Anti-CD3 and anti-CD28 mimic the
binding of the peptide:MHC complex to the T-cell
receptor and the binding of the co-stimulatory molecule
B7 to CD28, respectively. A fixed number (100 000) of
living cells were harvested following 0, 6, 24, 48 and 72 h
of stimulation, respectively, lysed, and stored at 801C
until mRNA extraction. The extraction of mRNA and
cDNA synthesis was performed as described above.
Real-time PCR product accumulation was monitored
in the ABI Prism 7300 Sequence Detector (Applied
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Biosystems, Foster City, CA, USA) using the intercalating
dye SYBR Green I. The reaction was carried out with the
2 SYBR Green PCR Master Mix, 3ml of cDNA, and
5 pmol of each specific primer (forward primer: 50-
ACTGATAATGTTGCTTCAACGG-30; reverse primer:
50-TCACCAGCTTCCTCAACCAC-30) in a total volume
of 15 ml. Thermocycling program was 40 cycles of 951C
for 10 min, 951C for 15 s, and 601C for 1 min with an
initial cycle of 501C for 2 min. All amplifications and
detections were carried out in capped 96-well optical
plates (Applied Biosystems).
Each sample was tested in duplicates to check for
reproducibility. To control for genomic DNA amplifica-
tion, NRT controls were run in duplicates for each
sample.
The ‘mRNA Induction index’ of PTPN22 was calcu-
lated using the formula 2DCT , where DCT is the CT value
at the stimulation time in question minus the CT value at
0 h (non-stimulated cells).
Using the same experimental conditions as in the
present study, previous experiments in our laboratory
have revealed that the mRNA expressions of eight
frequently used reference genes including GAPDH and
b-actin, fluctuate during stimulation of PBMCs (unpub-
lished data). The expression level of reference genes is
therefore unreliable for normalizing the quantitative RT-
PCR assay in the present study and hence we normalized
the expression of PTPN22 in cells stimulated for different
time periods to the input cell number.27
The fluorescent PCR-RFLP analysis was performed as
described above with 32 cycles in the PCR.
Search for potential targets of estrogen receptor by identifying
estrogen response elements in the promoter of PTPN22. The
web-based program PAGen@UIC28 was used to search
for transcription factor binding sites in the promoter of
the PTPN22 gene.
Statistical analysis
Two-way Repeated Measures ANOVA was used to
compare the relative expression of the T-allele in gDNA
and cDNA samples between and within the different
sample groups. One-way Repeated Measures ANOVA
was used to compare the changes in the mRNA
Induction index of PTPN22, and the relative expression
of the T-allele in cDNA samples from anti-CD3 and anti-
CD28 stimulated PBMCs over time. When required, data
were log(xþ 1) transformed to satisfy the ANOVA
assumption of homogeneity of variances. Po0.05 were
considered statistically significant. For every ANOVA,
P-values were Bonferroni adjusted for the number of
comparisons made.
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